VT-464 is an oral drug that stops your body from making androgens, which are hormones such as testosterone that can help prostate cancer cells to grow. Castration-resistant prostate cancer develops and progresses as the cancer adapts to be able to continue to grow in low levels of androgens in the body. VT-464 may lead to cancer shrinkage by preventing both your body and the tumor from producing androgens after progressing on enzalutamide or abiraterone.
The purpose of this study is to determine how well the cancer is responding to treatment with VT-464. The study will also examine the safety of VT-464. Finally, we will be studying different properties of the cancer before treatment to look for clues that may help us know which patients are most likely to respond to this drug in the future.
This study will evaluate how the drug affects you. This study drug is considered experimental and has not been approved by the FDA for the treatment of prostate cancer, however this is the fourth study using VT-464 in people. Early studies have shown that VT-464 leads to decreased PSA levels and stopped the tumor growth in some patients who have progressed after being treated with enzalutamide or abiraterone.
For more information about the study or for enrollment details, please contact the UCLA Urology Clinical Trials Office - (310) 206-5930.